Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted. The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov. Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

NLM Logo

pralsetinib MeSH Supplementary Concept Data 2025


MeSH Supplementary
pralsetinib
Unique ID
C000655704
RDF Unique Identifier
http://id.nlm.nih.gov/mesh/C000655704
Entry Term(s)
BLU-667
Cyclohexanecarboxamide, N-((1S)-1-(6-(4-fluoro-1H-pyrazol-1-yl)-3-pyridinyl)ethyl)-1-methoxy-4-(4-methyl-6-((5-methyl-1H-pyrazol-3-yl)amino)-2-pyrimidinyl)-, trans-
gavreto
trans-N-((1S)-1-(6-(4-Fluoro-1H-pyrazol-1-yl)-3-pyridinyl)ethyl)-1-methoxy-4-(4-methyl-6-((5-methyl-1H-pyrazol-3-yl)amino)-2-pyrimidinyl)cyclohexanecarboxamide
Pharm Action
Antineoplastic Agents
Registry Numbers
0
Heading Mapped to
*Pyrazoles
*Pyridines
*Pyrimidines
Frequency
48
Note
RET inhibitor
Source
Cancer Discov. 2018 Jul;8(7):836-849.
Date of Entry
2019/12/16
Revision Date
2021/07/21
pralsetinib Preferred
BLU-667 Narrower
trans-N-((1S)-1-(6-(4-Fluoro-1H-pyrazol-1-yl)-3-pyridinyl)ethyl)-1-methoxy-4-(4-methyl-6-((5-methyl-1H-pyrazol-3-yl)amino)-2-pyrimidinyl)cyclohexanecarboxamide Broader
gavreto Narrower
page delivered in 0.005s